173 related articles for article (PubMed ID: 31497954)
21. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
[TBL] [Abstract][Full Text] [Related]
22. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
24. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
25. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
[TBL] [Abstract][Full Text] [Related]
27. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
[TBL] [Abstract][Full Text] [Related]
28. Promiscuity and selectivity of small-molecule inhibitors across TAM receptor tyrosine kinases in pediatric leukemia.
Liu MH; Chen SB; Yu J; Liu CJ; Zhang XJ
J Mol Graph Model; 2017 Aug; 75():125-131. PubMed ID: 28551502
[TBL] [Abstract][Full Text] [Related]
29. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
30. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
31. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
32. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
33. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
34. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
35. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
36. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Koopman LA; Terp MG; Zom GG; Janmaat ML; Jacobsen K; Gresnigt-van den Heuvel E; Brandhorst M; Forssmann U; de Bree F; Pencheva N; Lingnau A; Zipeto MA; Parren PW; Breij EC; Ditzel HJ
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31600169
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
38. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S
Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404
[TBL] [Abstract][Full Text] [Related]
39. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
40. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M; Ben-Batalla I; Loges S
Expert Rev Hematol; 2015 Apr; 8(2):135-8. PubMed ID: 25578023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
